Although the overall cure rate for lung cancer is not improving it has become increasingly recognised over the last 10 years that accurate subclassification of tumour cell types and determining the extent of the disease at presentation are the two most impor-
tant steps that allow treatment decisions to be made.
The need for precise classification of the anatomical extent or stage of lung cancers led to the application of the tumour nodal involvement metastasis (TNM) system to this disease in 1973 (table) . The first report on 2000 cases studied by the American Task Force for Lung Cancer' showed that the anatomical stage of lung cancer at presentation clearly influenced prognosis in squamous and large cell tumours and adenocarcinomas. The size of the tumour, whether it was peripheral in the lung, and the presence or absence of evidence of nodal spread were the most important factors. The natural history of squamous cell cancers was more favourable than that of adenocarcinoma, which was in turn more favourable than that of large cell tumours when they were matched for stage. Small cell lung cancers formed an entirely different category as no staging grade had any apparent influence on survival. The propensity of this cell type to disseminate early is such that it has now come to be regarded as disseminated at presentation, and is treated systemically by cytotoxic chemotherapy in all but a tiny proportion of cases. This editorial evaluates the investigations currently available for staging lung cancer and suggests which tests should be carried out and when.
Staging of non-small cell cancer
The prognosis of squamous cell carcinoma, adenocarcinoma, and large cell cancers (that is, non-small cell lung cancers) depends heavily on successful surgical intervention. The introduction of the TNM staging system has encouraged an ordered assessment for selecting those cases most suitable for surgery; it has improved the rate of resection and should result in an improvement over the present five year survival of 25 % and the 10 year survival of 16-18% for all operated cases.2-5 Most will agree that stage I and stage II patients (table) should be operated on, and that stage III disease is inoperable. The emphasis in preoperative staging must therefore be to assess those factors that cause a neoplasm to become stage III-that is, T3, N2, and/or Ml. Not all surgeons, however, as yet undertake routine preoperative staging and the average survival data are downgraded by subjecting patients with a poor prognosis to surgery. Careful staging prevents the distress of unnecessary thoracotomy for incurable patients.
At the time of diagnosis up to two thirds of (8), adrenals (7), bone (6), retrocrural nodes (4), and spleen (2). Only 10 cases were proved by biopsy.
Other studies in progress suggest an incidence of about 10% for asymptomatic cerebral deposits in patients with non-small cell lung cancer being assessed for surgery-but most of these had other asymptomatic metastases in the mediastinum (most commonly) and abdomen, suggesting that the additional computed tomography brain scan The site, size, and cell type of the tumour also influence the likelihood that mediastinoscopy will show disease. For well differentiated peripheral tumours of less than 3 cm there is a very low incidence of mediastinal disease, while for undifferentiated tumours, larger masses, or central lesions visible at bronchoscopy the incidence of positive mediastinal lymph nodes at biopsy, despite no mediastinal abnormality visible on chest radiographs, is up to 50%. Thus with a well differentiated non-small cell tumour of less than 3 cm one may proceed direct to thoracotomy provided that the chest radiograph shows no mediastinal abnormality. Larger tumours or central lesions should, however, have mediastinal exploration whatever the cell type and degree of differentiation.
For most lesions mediastinal exploration is best undertaken by cervical mediastinoscopy, which allows assessment of both paratracheal chains and a limited examination of the main carinal nodes. Left upper lobe tumours require special consideration, however, as the lymphatic drainage is affected by the presence of the aortic arch and tumours within that lobe can affect anterior mediastinal, paraaortic, and other gland groups in the subaortic fossa that are not easily accessible by mediastinoscopy. It has been shown" 12 that the staging of left upper lobe tumours is improved if mediastinoscopy is supplemented by left anterior mediastinotomy. This is an extrapleural approach to the subaortic fossa through an incision in the left second intercostal space.
Pearson'3 noted a wide range of survival rates in series of patients with positive findings at mediastinoscopy, ranging from nil to 29% at five years, the higher rates coming from uncontrolled studies that 404 included preoperative radiotherapy.'4'5 A similar range of survival rates is reported for those patients whose mediastinal disease became apparent only at thoracotomy, after negative findings at mediastinoscopy: five year survival rates have ranged from nil to 41% with or without adjuvant radiotherapy or chemotherapy.'6 There is, however, considerable difficulty in interpreting these data owing to lack of precision in reporting the sites of mediastinal node disease at thoracotomy and whether the metastatic disease was macroscopic or microscopic. The results of these studies on surgical series strengthen the case for precise anatomical staging of the mediastinal node stations at thoracotomy if we are to attempt to identify particular sites that may be affected within the mediastinum, but they do not necessarily represent an absolute criterion of inoperability. A recent statement by the American Thoracic Society'7 draws attention to the variability in the reporting of surgical results for patients with N2 disease and suggests guidelines for detailed mediastinal lymph node mapping to identify the more favourable prognostic factors as an alternative to the polarised approach to mediastinal disease that is prevalent.
Pearson et al'6 have proposed some guidelines for identifying "favourable" factors in positive mediastinoscopy findings. After excluding the great majority of patients with mediastinal disease from surgery (those with superior mediastinal node disease, contralateral spread, extracapsular spread, or fixation to mediastinal structures), they proceeded to thoracotomy in a small group of patients with ipsilateral node disease in low paratracheal glands or in tracheobronchial or anterior subcarinal glands or both, but they achieved only a 9% five year survival rate overall. By contrast, another group of 62 patients with negative mediastinoscopy findings who were subsequently found to have metastatic disease in the mediastinum at thoracotomy achieved a five year survival rate of 24%, with a considerable advantage for squamous cell cancers. These results are made harder to interpret because preoperative or postoperative irradiation was used in a considerable number of the patients, but there seemed no obvious advantage in the addition of radiotherapy.
Clearly the general application of mediastinal exploration as a preoperative staging investigation will prevent unnecessary thoracotomies, and it is hoped that careful nodal mapping both at mediastinoscopy and at thoracotomy will be performed in future studies to settle the question of whether patients with any mediastinal disease should have a pulmonary resection and if so which patients.
Non-invasive assessment of the mediastinum The recent advances in non-invasive diagnostic imaging, such as computed tomography, have been used to assess whether they might take the place of mediastinoscopy with consequent saving of theatre time, morbidity, and so on. Computed tomography has a clear advantage over plain radiography '8-20 and conventional tomography2021 in the detection of mediastinal lymphadenopathy.
Several studies have compared computed tomography staging of the mediastinum with mediastinoscopy and postsurgical staging. Studies using the first generation of computed tomography scanners with scanning times of 18-20 seconds found a low sensitivity in detecting mediastinal adenopathy-44% 22 50%,8 77%,23 and 75%.24 With the use of newer models with a scanning time of 2-3 seconds the sensitivity has improved to 80%24 94%. 21 The decision as to whether a node is abnormal or not is an arbitrary one based on size, most reports assuming a 1-5 cm diameter as the upper limit of normal. Nodes may, however, enlarge owing to reactive hyperplasia or previous inflammatory change (for example, that of tuberculosis) and may cause false positive scans. Not surprisingly therefore the resultant specificity (true negative/true negative + false positive) of computed tomography has varied from 94%,18 with only two false positive mediastinal scans in 51 examinations, to 63 %,20 with 9/24 false positive scans. Another common cause for false positive results is associated atelectasis, causing the margins of the lung and mediastinum to become difficult to identify with computed tomography. In general, computed tomography of the mediastinum will give false positive scans with regard to lymphadenopathy in about 25% of cases.
A further potential advantage of computed tomography scanning is its ability to identify tumour invasion of the surrounding pleura and chest wall in addition to the mediastinum itself. Microscopic mediastinal invasion will be missed by computed tomography and is often not detected at mediastinal exploration. Such invasion may also be missed at thoracotomy unless routine sampling of node stations is undertaken. It is possible that these patients do benefit from surgery.'6 The main advantage of computed tomography is that it can save unnecessary mediastinoscopies. Since, however, it tends to " overstage" tumours, thoracic surgical units without computed tomography scanners will achieve equally good results with routine preoperative mediastinal exploration.
Another non-invasive staging techniquealthough rarely used in Britain-is scanning with the tumour seeking isotope gallium-67. Gallium-67 is not a tumour specific isotope and will be taken up wherever there is an inflammatory process in the thorax-for example, lymphadenopathy due to tuberculosis, sarcoidosis, or an abscess-but abnormal accumulation of the isotope will occur in 85-90% of all primary lung cancers. Within the thorax the results with gallium-67 are broadly similar to those obtained with computed tomography. Gallium scanning is more sensitive than plain radiography. 25 Its sensitivity for mediastinal metastatic deposits in lymph nodes is about 80%,25-27 although only those cases where the primary tumour takes up gallium can be realistically assessed. Specificity is also in the region of 80%. While it has been suggested that a positive gallium scan has a sufficiently high predictive accuracy to make mediastinoscopy unnecessary, this view must be criticised as the scans fail to show the anatomical detail seen with computed tomography and would not distinguish nodal disease from mediastinal invasion. This is an important distinction in a few patients and mediastinoscopy would be a helpful procedure. Surgical staging In those patients who come to thoracotomy it is important that the staging process is continued. The surgeon's first task is to check the accuracy of preoperative staging, particularly for the unexpected presence and extent of mediastinal gland metastases. If systematic preoperative mediastinal staging has been undertaken the number of irresectable tumours should not exceed 5 %,13 but there may occasionally be cases where the surgeon's preoperative assessment has been so misleading that even at this late stage it is better not to proceed with resection. Mediastinal glands should be sampled from around the pulmonary hilum, routinely including the main carinal glands and one other adjacent gland station. Ideally these glands should undergo frozen section analysis but this is difficult logistically and most surgeons rely on macroscopic appearances. The use of long ambiguous terms to describe gland positions is best avoided. An arbitrary gland numbering system such as those proposed by the American Joint Committee on Cancer Staging and by the American Thoracic Society'' works well in practice. If resection is subsequently undertaken all glands left on the specimen should therefore be Ni disease.
Despite careful preoperative staging the surgeon may discover macroscopic N2 disease either where the mediastinal exploration has been inaccurate or where glands beyond the reach of the mediastinoscope are discovered. The former case becomes rare with experience but should give rise to careful reconsideration of resectability. In the latter case resection is probably still justified.'6 A further 10% of resections will be found to be N2 only on microscopic analysis of resected nodes.23
Pathological staging It is possible to restage patients as information becomes available from follow up. For practical purposes, however, the most accurate assessment is reached after microscopic analysis of the resected specimens, when a postsurgical treatmentpathological staging (pTNM) can be made. To be meaningful this requires careful presurgical staging to look for distant metastases, routine sampling of mediastinal gland stations at thoracotomy, and microscopic examination by a pathologist aware of the features of a tumour that affect its stage. The pathologist cannot be expected to differentiate hilar from mediastinal glands included in a resection specimen-this can be difficult enough for the surgeon at thoracotomy. The mediastinal glands should be sent separately and numbered clearly (see above). The pathology report should include comments on the cell type and its differentiation, homogeneity of cell type, pleural disease in the case of peripheral tumours, resection margins and bronchial stump, and the extent of glandular extension and whether such extension is intracapsular or locally invasive.
Staging in small cell lung cancer
The particularly high incidence of mediastinal lymph node disease in small cell lung cancer and coexisting evidence of extrathoracic dissemination at presentation mean that the TNM classification has no bearing on prognosis. Recent surgical series have confirmed the very small number of patients with small cell lung cancers who have truly stage I disease,29 and large surgical series have included no long term survivors after resection.' 30 In the few cases where the primary tumour is peripheral, however, survival rates are more favourable, particularly if no nodes are affected; for example, a 60% five year survival rate has been reported in 26 
Conclusions
The failure to improve survival in lung cancer is due, firstly, to the very high incidence of obvious inoperability at presentation and, secondly, the lack of sufficiently sensitive tests to identify small metastases in patients otherwise thought curable. Accurate mediastinal staging can make a major contribution to the decision whether to operate. Routine mediastinoscopy will lower the frequency of unnecessary thoracotomies and increase the resectability rate. In the great majority of cases positive findings at mediastinoscopy are associated with incurable disease. In a select group of patients, however-those with squamous cell tumours of the right lung with ipsilateral low superior mediastinal node disease-surgery may still be appropriate. If the findings at preoperative mediastinoscopy are negative and affected glands are found low in the mediastinum at thoracotomy, resection may be beneficial, with a five year survival rate reportedly as high as 41 %.16 Thus thoracotomy resulting from the lack of sensitivity of mediastinoscopy (71 %23) is not entirely unjustifiable, while the 100% specificity of a positive result23 ensures that no one is denied surgery inappropriately.
Computed tomography can reduce the number of mediastinoscopies but its specificity is not sufficiently high to eliminate the need for mediastinoscopy in patients with positive scans. Positive findings on computed tomography may also assist by directing the surgeon where to take biopsy samples during mediastinoscopy.
The role of computed tomography in extrathoracic staging is not yet established, but conventional isotope scans are of use only in patients with organ specific or non-specific features suggestive of occult disease.
